Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy or chemotherapy, where treatment-induced fibrosis is a common complication associated with therapy. Since fibrosis is mostly driven by dysregulation of the Rho-ROCK signaling axis, researchers from Australia have investigated the potential of modulating ROCK2 with the small-molecule inhibitor RX-10616 for its potential antifibrotic effect combined with radiotherapy in patient-derived murine models of HNSCC.
Eli Lilly & Co. and Evotec International GmbH have disclosed Rho-associated protein kinase 2 (ROCK2) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis, and inflammatory and neurological disorders.
In Parkinson’s disease (PD), damaged mitochondria build up in the dopaminergic system of the substantia nigra, partly due to impaired mitochondrial autophagy (mitophagy) and autophagosome accumulation.
Redx Pharma plc has divulged Rho kinase 1 (ROCK1) and 2 (ROCK2) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, fibrosis, inflammatory and neurological disorders.
Genosco Inc. has divulged Rho-associated protein kinase 2 (ROCK2) inhibitors reported to be useful for the treatment of fibrosis, cancer, cardiovascular and inflammatory disorders.
Beijing Primegene Therapeutics Co. Ltd. has identified azacycloalkane compounds acting as rho kinase 1 (ROCK1; p160-ROCK) and/or rho-associated protein kinase 2 (ROCK 2) inhibitors reported to be useful for the treatment of asthma, cancer, insulin resistance, neurodegeneration, osteoporosis and renal failure.
Graviton Bioscience BV has divulged new Rho-associated protein kinase 2 (ROCK2) inhibitors reported to be useful for the treatment of arteriosclerosis, cancer, idiopathic pulmonary fibrosis, metabolic syndrome, multiple sclerosis, psoriasis, scleroderma and uveitis, among others.
Graviton Bioscience Corp. has announced a strategic investment from Sanofi SA. Under the agreement, Sanofi receives a right of first negotiation to license compounds across various indications, including immunological and metabolic syndrome indications.
Graviton Bioscience BV has described Rho kinase 2 (ROCK 2; ROCKα) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, lung, cardiovascular, eye, inflammatory and neurological disorders.
Redx Pharma plc has identified Rho kinase 1 (ROCK 1; p160-ROCK) and/or rho kinase 2 (ROCK 2; ROCKα) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, inflammatory and neurological disorders.
